Chiral pharmacology and its consequences for therapeutic monitoring.
The individual enantiomers of chiral drugs may have profound differences in their pharmacologic and toxicologic properties. Their metabolism and pharmacokinetics may also differ markedly, and the presence of one enantiomer may inhibit the metabolism of the other. Stereospecificity is required in analytical methods, whether these be chromatography or radioimmunoassay.
D002845:Chromatography / Q000379:methods; D004347:Drug Interactions; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007700:Kinetics; D004364:Pharmaceutical Preparations / Q000097:blood*; D011863:Radioimmunoassay; D011869:Radioligand Assay; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D004364:Pharmaceutical Preparations